Myomo, Inc.
Moat Score — Myomo, Inc.
Total Moat Score
13 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Myomo holds 35 issued patents (14 pending) on its myoelectric MyoPro EMG-sensing and actuation technology, and is, by its own 10-K characterization, the only commercially available device in the U.S. that lets partially paralyzed users regain arm movement using their own residual muscle signals -- a genuinely hard-to-replicate clinical and engineering position. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a ~200-employee company manufacturing custom-fabricated devices at a single Burlington, MA facility (120 units/month capacity), Myomo has no scale-driven cost advantage and in fact carries the cost burden of custom fitting and clinical evaluation for every unit sold. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 3 / 5 | Pricing is largely set administratively via CMS HCPCS codes L8701 (~$34,970) and L8702 (~$68,800 as of January 2026) rather than negotiated with patients, but because Myomo is the only reimbursable device in its category, it captures the full statutory fee with little downward pressure. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Each MyoPro fitting is an independent clinical transaction between Myomo, a patient, and a payer; no aspect of the product or business gets more valuable as additional patients or clinicians adopt it. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once a patient is custom-fit and trained on a MyoPro, switching to a different device means re-fitting and re-training from scratch, creating real but narrow lock-in confined to the individual patient rather than an institutional or recurring-purchase relationship. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | The total addressable population of partial upper-limb paralysis patients who qualify for reimbursement is small enough that it has not attracted large orthotics incumbents, leaving Myomo's direct competition limited mainly to early-stage exoskeleton makers (Lifeward, Ekso Bionics) and newer O&P entrants rather than deep-pocketed med-tech majors. |